Getting itchy dogs back to normal
Zenrelia™ gets nearly 50% more itchy dogs back to normal than Apoquel®1††

A higher proportion of dogs treated with Zenrelia achieved a PVAS (Pruritis Visual Analogue Scale) score of less than two by day 112, compared to dogs treated with Apoquel. A 'normal' itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS<2)1.

Zenrelia offers significant improvement in skin lesions vs. Apoquel from day 281†††
The Canine Atopic Dermatitis Extent & Severity Index (CADESI) is a tool to help measure the level of skin lesions in dogs, used widely in clinical studies.4
Vet-assessed skin lesion score (CADESI-04)

Study Design and Key Inclusion/Exclusion Criteria1
How Zenrelia works
Zenrelia is the only JAK inhibitor with high potency for JAK1, JAK2 & TYK2, key JAK enzymes involved in itch and inflammation¥, 5-7. By targeting multiple JAK enzymes & inhibiting the function of several cytokines involved in itch and inflammation, Zenrelia gets more itchy dogs back to normal than Apoquel, with a comparable safety profileα**1,5,6,8,9.
The best way to evaluate a JAK inhibitor efficacy and safety is through head to head real-world studies9,10. JAK selectivity based on in vitro assays shouldn't be used in isolation to evaluate product efficacy and safety10.
Questions?
Zenrelia Resources
* Referenceable claims in digital & social copy can be found on this page. Full reference list below.
** 77% of dogs treated with Zenrelia achieved PVAS <2 by day 112 compared to 53% of dogs treated with Apoquel. A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS <2)1.
BID, twice-daily; IRTT, investigator-assessed response to treatment; ORTT, owner-assessed response to treatment; SID, once daily; VAS, visual analogue scale.
†Response to treatment was assessed using a simple VAS scale graded from 'no improvement' at 0 cm to 'excellent improvement' at 10 cm1.
††A ‘normal’ itch score is considered to be comparable to that of a healthy, non-allergic dog (PVAS<2)1.
†††Improvement based on mean CADESI-04 scores from Day 28. A CADESI-04 score of <10 is comparable to that of a healthy, non-allergic dog1.
‡ 79% of owners expect a PVAS of 0-1.92.
¥ Multiple JAK enzymes are involved in itch and inflammation, in particular JAK1,JAK2 & TYK211.
α Proinflammatory & pruritogenic cytokines implicated in allergic skin disease & allergic responses include IL-2, IL-6, IL-4,, IL-13 & IL-316.
- Forster S et al. Vet Dermatol 2025 Apr,36(2):165-176.
- Rybnícek J. et al. Vet Dermatol 2009;20(2):115–122.
- Hill P. B. et al. Vet Dermatol 2007;18(5):301–308.
- Olivry T et al. Vet Dermatol. 2014 Apr;25(2):77–85, e25.Schwartz DM et al.
- Unpublished data: JAK selectivity profile report.
- Gonzalez AJ et al. J. vet. Pharmacol. Therap. 37, 317--324.
- Howell MD, Kuo FI and Smith PA. Front. Immunol 2019;10:2342. doi: 10.3389/fimmu.2019.02342.
- Zenrelia Summary of Product Characteristics.
- Virtanen A, et al. Arthritis & Rheumatology. 2023 Nov;75(11):2054-61.
- Bonelli M, et al. Ann Rheum Dis 2024;83:139-160.
- Lin CM, Cooles FA, Isaacs JD. Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):100-104.